Andra AP fonden Has $1.58 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

Andra AP fonden cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 86.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,000 shares of the biopharmaceutical company’s stock after selling 18,500 shares during the quarter. Andra AP fonden’s holdings in Regeneron Pharmaceuticals were worth $1,575,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in REGN. Brighton Jones LLC lifted its stake in shares of Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after acquiring an additional 686 shares during the last quarter. World Investment Advisors bought a new stake in Regeneron Pharmaceuticals during the 1st quarter worth $230,000. Alps Advisors Inc. increased its holdings in Regeneron Pharmaceuticals by 71.0% in the 1st quarter. Alps Advisors Inc. now owns 530 shares of the biopharmaceutical company’s stock worth $336,000 after purchasing an additional 220 shares in the last quarter. SteelPeak Wealth LLC raised its position in Regeneron Pharmaceuticals by 28.1% in the first quarter. SteelPeak Wealth LLC now owns 3,615 shares of the biopharmaceutical company’s stock valued at $2,293,000 after purchasing an additional 792 shares during the last quarter. Finally, B & T Capital Management DBA Alpha Capital Management boosted its stake in shares of Regeneron Pharmaceuticals by 11.5% during the first quarter. B & T Capital Management DBA Alpha Capital Management now owns 3,510 shares of the biopharmaceutical company’s stock valued at $2,226,000 after purchasing an additional 363 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 1.6%

NASDAQ REGN opened at $657.53 on Friday. The company has a market cap of $69.69 billion, a price-to-earnings ratio of 15.75, a P/E/G ratio of 2.03 and a beta of 0.31. The business has a 50 day moving average price of $588.03 and a 200-day moving average price of $568.04. The company has a quick ratio of 3.72, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $834.42.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. The firm had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business’s quarterly revenue was up .9% compared to the same quarter last year. During the same period last year, the firm earned $12.46 earnings per share. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.43%.

Wall Street Analyst Weigh In

REGN has been the subject of several recent research reports. UBS Group upped their price objective on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a research note on Friday. Rothschild & Co Redburn started coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, August 14th. They set a “buy” rating and a $890.00 price target on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 8th. Redburn Atlantic upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, August 14th. Finally, BMO Capital Markets raised their price target on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a report on Monday, August 4th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $796.57.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 6,500 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the transaction, the director directly owned 2,352 shares of the company’s stock, valued at $1,538,843.04. The trade was a 73.43% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 7.02% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.